Biological
Fluarix clinical trials
- studies test it
- 21
- open now
- 0
- in phase 3
- 8
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2006 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 7 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
- Phase 3
- 8
- Phase 4
- 6
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 5
GlaxoSmithKline (15) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Centers for Disease Control and Prevention (1) · Public Health England (1) · University of Massachusetts, Worcester (1) · NanoPass Technologies Ltd (1)
Often tested with
Tested in the same studies.
Influenza Vaccines (6) · FluBlok (1) · Fluzone High-Dose (1) · Boostrix (1) · Meningococcal Vaccines (1) · Pandemrix (1) · FluLaval (1) · Afluria (1)
Studies
Open first, then newest update. How each study uses fluarix is read from its arms, and is right about nine times in ten.
Testing it · 21
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCPCompletedPhase 4Centers for Disease Control and PreventionNCT03722589Written as Fluarix
- Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedPhase 3GlaxoSmithKlineNCT00385255Written as Fluarix®
- Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.CompletedPhase 4GlaxoSmithKlineNCT00750360Written as FluarixTM
- Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™CompletedPhase 4GlaxoSmithKlineNCT00377611Written as Fluarix™
- Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old AdultsCompletedPhase 3GlaxoSmithKlineNCT00453986Written as Fluarix™
- Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™CompletedPhase 4GlaxoSmithKlineNCT01196026Written as Fluarix™
- Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTMCompletedPhase 4GlaxoSmithKlineNCT01190215Written as FluarixTM
- Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) StatusCompletedPhase 4Public Health EnglandNCT00442975Written as Fluarix
- Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in ElderlyCompletedPhase 2GlaxoSmithKlineNCT00968890Written as Fluarix™
- A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in AdultsCompletedPhase 3GlaxoSmithKlineNCT00706563Written as Fluarix™
- Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly PopulationCompletedPhase 2GlaxoSmithKlineNCT00318149Written as Fluarix
- Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in ChildrenCompletedPhase 3GlaxoSmithKlineNCT00764790Written as Fluarix
- Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in ChildrenCompletedPhase 3GlaxoSmithKlineNCT00383123Written as Fluarix™
- Immune Responses Induced by Different Licensed Influenza VaccinesCompletedNot applicableUniversity of Massachusetts, WorcesterNCT00902278Written as Fluarix
- Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult PopulationCompletedPhase 2GlaxoSmithKlineNCT00377585Written as Fluarix
- Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older AdultsCompletedPhase 3GlaxoSmithKlineNCT00380211Written as Fluarix
- Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly AdultsCompletedPhase 2GlaxoSmithKlineNCT00386698Written as Fluarix
- Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or AboveCompletedPhase 3GlaxoSmithKlineNCT00345904Written as Fluarix
- A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu VaccinesCompletedNot applicableNanoPass Technologies LtdNCT00558649Written as Flu Vaccine (FLUARIX®)
- Influenza Vaccine in Pregnant WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00905125Written as Fluarix®
See all 21 studies that test fluarix →
Given in every arm · 5 — fluarix is usual care beside what is tested
- A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedPhase 2Janssen Vaccines & Prevention B.V.NCT03339713Written as Fluarix
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of AgeCompletedPhase 2GlaxoSmithKlineNCT00397215Written as Fluarix
- Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy ChildrenCompletedPhase 1GlaxoSmithKlineNCT01096056Written as Fluarix
- Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)CompletedPhase 3GlaxoSmithKlineNCT00971425Written as Fluarix™
- A Study for Evaluation of GSK Biologicals' Pandemic Influenza VaccineWithdrawnPhase 3GlaxoSmithKlineNCT00866580Written as FluarixTM
As the comparator · 26 — what is tested is compared with fluarix
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT06602024Written as Fluarix®
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsCompletedPhase 2ModernaTX, Inc.NCT05606965Written as Egg-based Quadrivalent Influenza Vaccine
- Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT01711736Written as Fluarix
- Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy ChildrenTerminatedPhase 2GlaxoSmithKlineNCT01195779Written as Fluarix™
- Revaccination With Influenza Vaccine GSK1247446ACompletedPhase 2GlaxoSmithKlineNCT00545025Written as Fluarix™
- Study to Evaluate an Influenza Vaccine CandidateCompletedPhase 2GlaxoSmithKlineNCT00540228Written as Fluarix™
- Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in ChildrenCompletedPhase 2GlaxoSmithKlineNCT00502593Written as Fluarix™
- Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)CompletedPhase 3GlaxoSmithKlineNCT01204671Written as FluarixTM
- Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy ChildrenCompletedPhase 2GlaxoSmithKlineNCT00985790Written as Fluarix™
- Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly PeopleCompletedPhase 3GlaxoSmithKlineNCT00992784Written as FluarixTM
- Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenCompletedPhase 3GlaxoSmithKlineNCT01196988Written as FluarixTM
- Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldCompletedPhase 4GlaxoSmithKlineNCT01730378Written as Fluarix™
- Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT00760617Written as Fluarix
- Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AboveCompletedPhase 3GlaxoSmithKlineNCT00319098Written as Fluarix
- Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine CandidateCompletedPhase 2GlaxoSmithKlineNCT00385840Written as FluarixTM
- Study to Evaluate an Influenza Vaccine CandidateCompletedPhase 2GlaxoSmithKlineNCT00321373Written as FluarixTM
- Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedPhase 2GlaxoSmithKlineNCT00538473Written as Fluarix™
- Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389ACompletedPhase 2GlaxoSmithKlineNCT00540592Written as Fluarix
- Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedPhase 3GlaxoSmithKlineNCT00529516Written as Fluarix
- Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedPhase 2GlaxoSmithKlineNCT00538213Written as Fluarix™
Showing 20 of 26.